Financials

  • Market Capitalization 218.3 M
  • Employee 87
  • Founded 2015
  • CEO N/A
  • Website www.kerostx.com
  • Headquarter Massachusetts, United States
  • FIGI BBG00H1HP9G9
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-4.36
Price to sales ratio
13.69

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
3575
OBIO
Orchestra BioMed Holdings, Inc. - Ordinary Shares
3.65 USD-1.08%-6.89%-8.75%+24.15%218.56 M USD
3579
KPTI
Karyopharm Therapeutics Inc. - Common Stock
9.57 USD-4.40%-10.31%-0.73%-0.73%216.88 M USD
3587
SLGL
Sol-Gel Technologies Ltd. - Ordinary Shares
76.95 USD+2.07%+3.73%+5.40%+863.08%214.39 M USD
3590
NBP
NovaBridge Biosciences - American Depositary Shares
1.85 USD+2.78%-4.15%+14.91%-58.98%213.46 M USD

Frequently asked questions about Keros Therapeutics, Inc. - common stock

What is the Keros Therapeutics, Inc. - common stock stock price today?

The current price of Keros Therapeutics, Inc. - common stock (KROS) is 11.03. Over the past 24 hours, the stock has changed by +4.35%. Follow the KROS chart for real-time price dynamics.

What is the stock ticker of Keros Therapeutics, Inc. - common stock?

Keros Therapeutics, Inc. - common stock trades under the ticker KROS. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Keros Therapeutics, Inc. - common stock stock going up?

KROS has changed by -5.48% over the last week, +7.61% over the last month, and -26.95% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Keros Therapeutics, Inc. - common stock net income for the last quarter?

Keros Therapeutics, Inc. - common stock reported net income of -23.71 M for the last quarter. The previous quarter showed -23.46 M, which means net income changed by -1.05%.

How many employees does Keros Therapeutics, Inc. - common stock have?

As of the latest available data, Keros Therapeutics, Inc. - common stock has 87 employees. Workforce size can provide additional context about the company's scale and operations.

What is Keros Therapeutics, Inc. - common stock EBITDA?

Keros Therapeutics, Inc. - common stock EBITDA is -25.81 M, and its EBITDA margin is -80.65 K%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Keros Therapeutics, Inc. - common stock stock?

You can buy Keros Therapeutics, Inc. - common stock (KROS) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Keros Therapeutics, Inc. - common stock stock?

Investing in Keros Therapeutics, Inc. - common stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the KROS chart and related analysis on metatrader.com as part of your research.

News